MDM2 and cancer: There are a number of pre-clinical studies demonstrating the promise of targeting MDM2 via PPIs in cancers with either high endogenous MDM2 expression or targeting MDM2 following induction of MDM2 expression via DNA damaging agents [92,107,108,109,110,111,112].